News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
21,204 Results
Type
Article (1749)
Company Profile (9)
Press Release (19446)
Multimedia
Podcasts (1)
Webinars (1)
Section
Business (5454)
Career Advice (140)
Deals (811)
Drug Development (2642)
Employer Resources (30)
FDA (500)
Job Trends (588)
News (9925)
Policy (1378)
Tag
Academia (264)
Adcomms (1)
Allergies (1)
Alliances (1484)
ALS (15)
Alzheimer's disease (61)
Antibody-drug conjugate (ADC) (1)
Approvals (496)
Artificial intelligence (18)
Bankruptcy (6)
Best Places to Work (510)
BIOSECURE Act (1)
Biosimilars (1)
Biotechnology (6)
Brain cancer (1)
Breast cancer (9)
Cancer (78)
Cardiovascular disease (9)
Career advice (121)
Career pathing (2)
CAR-T (5)
Cell therapy (13)
Cervical cancer (1)
Clinical research (2163)
Collaboration (32)
Compensation (1)
COVID-19 (147)
C-suite (11)
Cystic fibrosis (3)
Data (99)
Depression (1)
Diabetes (10)
Diagnostics (165)
Diversity, equity & inclusion (19)
Drug discovery (7)
Drug pricing (4)
Duchenne muscular dystrophy (4)
Earnings (1537)
Editorial (6)
Employer branding (3)
Employer resources (28)
Events (2529)
Executive appointments (26)
FDA (558)
Funding (21)
Gene editing (1)
Generative AI (4)
Gene therapy (10)
GLP-1 (21)
Government (224)
Guidances (5)
Healthcare (862)
IgA nephropathy (1)
Immunology and inflammation (1)
Indications (2)
Infectious disease (148)
Inflammatory bowel disease (4)
Inflation Reduction Act (1)
Influenza (1)
Intellectual property (2)
Interviews (29)
IPO (313)
IRA (3)
Job creations (88)
Job search strategy (101)
Labor market (1)
Layoffs (8)
Leadership (1)
Legal (378)
Liver cancer (2)
Lung cancer (22)
Lymphoma (4)
Management (10)
Manufacturing (8)
MASH (3)
Medical device (353)
Medtech (353)
Mergers & acquisitions (515)
Metabolic disorders (17)
Multiple sclerosis (3)
Neurodegenerative disease (2)
Neuropsychiatric disorders (2)
Neuroscience (94)
NextGen: Class of 2025 (292)
Non-profit (344)
Now hiring (4)
Obesity (5)
Opinion (13)
Pain (3)
Pancreatic cancer (4)
Parkinson's disease (7)
Partnered (3)
Patents (8)
Patient recruitment (5)
People (2064)
Pharmaceutical (6)
Phase I (665)
Phase II (861)
Phase III (830)
Pipeline (52)
Policy (13)
Postmarket research (114)
Preclinical (214)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (10)
Rare diseases (7)
Real estate (185)
Recruiting (7)
Regulatory (883)
Reports (7)
Research institute (191)
Resumes & cover letters (15)
Schizophrenia (2)
Series A (1)
Series B (2)
Special edition (1)
Spinal muscular atrophy (1)
Sponsored (2)
Startups (89)
Stomach cancer (1)
Supply chain (3)
Tariffs (1)
The Weekly (1)
Vaccines (27)
Weight loss (1)
Women's health (2)
Date
Today (7)
Last 7 days (36)
Last 30 days (105)
Last 365 days (1080)
2025 (357)
2024 (1214)
2023 (1352)
2022 (1829)
2021 (1836)
2020 (1837)
2019 (1828)
2018 (1305)
2017 (1000)
2016 (1158)
2015 (1212)
2014 (890)
2013 (682)
2012 (764)
2011 (733)
2010 (661)
Location
Africa (62)
Arizona (2)
Arkansas (2)
Asia (1119)
Australia (359)
California (131)
Canada (70)
China (8)
Colorado (6)
Connecticut (8)
Delaware (2)
Europe (4411)
Florida (28)
Georgia (6)
Idaho (1)
Illinois (25)
Indiana (9)
Japan (7)
Maryland (33)
Massachusetts (126)
Michigan (4)
Minnesota (3)
Missouri (4)
Montana (1)
Nevada (1)
New Hampshire (1)
New Jersey (72)
New Mexico (1)
New York (42)
North Carolina (53)
North Dakota (1)
Northern California (46)
Ohio (12)
Oregon (1)
Pennsylvania (36)
Rhode Island (4)
South America (57)
South Carolina (1)
Southern California (54)
Tennessee (1)
Texas (43)
United States (677)
Utah (8)
Virginia (3)
Washington D.C. (7)
Washington State (8)
Wisconsin (7)
21,204 Results for "eth zurich".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Angle PLC Announces Parsortix Used in Research Paper from ETH Zurich
January 24, 2025
·
7 min read
Press Releases
Moss Genomics Launches “Perennial” Genomics Platform, Closes on 130 ETH
April 28, 2025
·
7 min read
Press Releases
Ethris Receives €10 Million EU4Health Grant to Support Clinical Development and Expand Antiviral Applications of Lead mRNA Candidate ETH47
May 6, 2025
·
4 min read
Press Releases
Ethris Presents Positive Topline Phase 1 Data with mRNA Lead Candidate ETH47 for Uncontrolled Asthma
January 30, 2025
·
4 min read
Drug Development
Ethris Announces $5 Million in Funding to Prepare Lead Candidate ETH47 for Phase 2 Study
Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced that it has received funding from the Gates Foundation to support the advancement of the company’s lead mRNA-based product candidate, ETH47.
June 18, 2024
·
3 min read
Drug Development
Ethris Announces Positive Initial Phase 1 Data Demonstrating Nasal Delivery of mRNA Lead Candidate ETH47
Ethris GmbH announced preliminary positive data from its Phase 1 dose escalation clinical trial evaluating the safety, tolerability, and target engagement of lead mRNA candidate ETH47 encoding interferon lambda, in healthy participants.
June 25, 2024
·
3 min read
Press Releases
Moss Genomics Announces Closing of Private Placement, Acquisition of 160 Ethereum Cryptocurrency (ETH) and Welcomes Hunter Jordan to Its Board of Directors
February 3, 2025
·
5 min read
Drug Development
Ethris Initiates First-in-Human Dosing in Phase 1 Study of ETH47 for the Treatment of Virus-Induced Asthma
Ethris GmbH announced the dosing of the first healthy participant in its first-in-human study of lead candidate ETH47, which was developed using Ethris’ Stabilized Non-Immunogenic mRNA platform and encodes for type III interferon that plays a vital role in early antiviral response.
December 18, 2023
·
4 min read
Drug Development
Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections
Ethris GmbH announced that it has received approval from the United Kingdom Medicines and Healthcare products Regulatory Agency to proceed with a Phase 1 clinical trial for its inhaled mRNA program, ETH47, in healthy participants for the treatment and prophylaxis of respiratory viral infections.
November 28, 2023
·
2 min read
Ninety One, Inc. Partners with the Multi-Scale Robotics Lab at ETH Zurich to Advance Robotic Surgery Through Machine Learning and Artificial Intelligence
The Multi-Scale Robotics Lab (MSRL) at ETH Zurich and Ninety One, Inc have partnered to advance Precision Medicine and Surgical Robotics through advanced Artificial Intelligence and Machine Learning.
May 26, 2020
·
2 min read
1 of 2,121
Next
